胡杨杨,李淑萍,张 芃,李松涛,赵凤春.RhD正定型及不规则抗体筛查的临床意义分析[J].现代生物医学进展英文版,2020,(4):693-697. |
RhD正定型及不规则抗体筛查的临床意义分析 |
Clinical Significance Analysis of RhD Positive and Irregular Antibody Screening |
Received:August 06, 2019 Revised:August 31, 2019 |
DOI:10.13241/j.cnki.pmb.2020.04.019 |
中文关键词: RhD正定型 不规则抗体筛查 临床意义 |
英文关键词: RhD positive definite Irregular antibody screening Clinical significance |
基金项目:国家自然科学基金项目(81371861) |
Author Name | Affiliation | E-mail | HU Yang-yang | Department of Blood Transfusion, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China | huyangyang2019@126.com | LI Shu-ping | Department of Blood Transfusion, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China | | ZHANG Peng | Department of Blood Transfusion, Beijing Hospital, Beijing, 100730, China | | LI Song-tao | Department of Blood Transfusion, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China | | ZHAO Feng-chun | Department of Blood Transfusion, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China | |
|
Hits: 721 |
Download times: 339 |
中文摘要: |
摘要 目的:探究RhD正定型及不规则抗体筛查在预防临床输血不良反应中的应用价值及临床意义。方法:回顾性分析2010年至2011年、2017年至2018年于首都医科大学附属北京同仁医院输血科实施输血治疗的1892例患者,将2010年至2011年未实施RhD正定型及不规则抗体筛查时输血治疗的901例患者设为对照组,将2017年至2018年实施RhD正定型及不规则抗体筛查后输血治疗的991例患者设为观察组。对比两组输血不良反应发生率,分析不同血液成分、不同性别、不同年龄输血不良反应发生率,并就2017年、2018年受血者RhD正定型及不规则抗体特异性分布进行罗列。结果:(1)2010年输血不良反应发生率为3.49 %,2011年为2.40 %,2017年为1.33 %,2018年为0.74 %,对照组不良反应发生率明显高于观察组(P<0.05)。(2)观察组不同血液成分输血的不良反应发生率显著低于对照组(P<0.05)。(3)两组不同年龄和性别输血不良反应发生率对比差异无统计学意义(P>0.05)。(4)观察组共检出20例RhD正定型及不规则抗体阳性患者,其中抗-M型5例,抗-D型3例,抗-E型2例,抗-C型2例,抗-P型2例,抗-LEa型1例,抗-LEb型1例,抗-JKa型1例,抗-N型1例,抗-H型1例,非特异性抗体1例。结论:RhD正定型及不规则抗体筛查能够显著降低输血不良反应发生率,有助于提高配血的准确性,提高输血治疗的安全性。 |
英文摘要: |
ABSTRACT Objective: To explore the application value and clinical significance of RhD positive and irregular antibody screening in prevention of clinical transfusion adverse reactions. Methods: Retrospective analysis of transfusion therapy in Department of Blood Transfusion, Beijing Tongren Hospital, Capital Medical University(our hospital) from 2010 to 2011 and from 2017 to 2018. 1892 patients were enrolled in the study. 901 patients who received blood transfusion therapy during RhD positive and irregular antibody screening from 2010 to 2011 were used as the control group. RhD positive stereotypes and irregular antibodies will be implemented from 2017 to 2018. 991 patients who were treated with blood transfusion after screening were set as the observation group. The incidence of adverse reactions of transfusion was compared between the two groups. The incidence of adverse reactions of different blood components, different genders, different ages was analyzed, and the recipients of blood in 2017 and 2018 were compared. The specific distribution of RhD positive and irregular antibodies was listed. Results: (1) The incidence of adverse reactions of transfusion in 2010 was 3.49 %, 2.40 % in 2011, 1.33 % in 2017, and 0.74 % in 2018. The incidence of adverse reactions in the control group was significantly higher than that in the observation group (P<0.05). (2) The incidence of adverse reactions in different blood transfusion of the observation group was significantly lower than that of the control group (P<0.05). (3) There was no significant difference in the incidence of adverse reactions of transfusion between the two groups of different genders and ages (P>0.05). (4) A total of 20 patients with RhD positive and irregular antibody positive were detected in the observation group, including 5 cases of anti-M type, 3 cases of anti-D type, 2 cases of anti-E type, 2 cases of anti-C type, 2 cases of anti-P type, 1 case of anti-LEa type, 1 case of anti-LEb type, 1 case of anti-JKa type, 1 case of anti-N type, 1 case of anti-H type, and 1 case of non-specific antibody. Conclusion: RhD positive Styling and irregular antibody screening can significantly reduce the incidence of adverse reactions of transfusion, help to improve the accuracy of blood matching, and improve the safety of blood transfusion therapy. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|